Literature DB >> 23188178

Fifteen million people on antiretroviral treatment by 2015: treatment as prevention.

Reuben Granich1, Brian Williams, Julio Montaner.   

Abstract

PURPOSE OF REVIEW: The declaration of the United Nations High Level meeting on AIDS in June 2011 includes 10 concrete targets, including to ensure that there are 15 million people living with human immunodeficiency virus (HIV) on antiretroviral treatment (ART) by 2015. This review examines the potential, opportunities and challenges of treatment as prevention of HIV and tuberculosis (TB) in reaching this target. RECENT
FINDINGS: Although around 8 million people are on treatment, everyone living with HIV will eventually need ART to stay alive. As many as 24  million people living with HIV today are not on treatment, the majority not even being aware of their HIV infection. Expansion of a comprehensive prevention strategy including providing ART to 15 million or more people would significantly reduce HIV and TB morbidity, mortality and transmission. The challenges include ensuring human rights protections, steady drug supply, early diagnosis and linkage to care, task shifting, adherence, retention, and monitoring and evaluation. Expansion could also lead to the control and possible elimination of HIV in many places.
SUMMARY: Achieving an 'AIDS-free generation' whereby deaths related to HIV are drastically reduced, people living with HIV are AIDS-free on ART, and HIV transmission is decreased, is both scientifically sound and practically feasible. The global community could reach 15 million people on ART by 2015 while expanding our vision and efforts to include diagnosis and treatment for all the 32  million people living with HIV in the future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23188178     DOI: 10.1097/COH.0b013e32835b80dd

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  26 in total

1.  Behavioral intervention improves treatment outcomes among HIV-infected individuals who have delayed, declined, or discontinued antiretroviral therapy: a randomized controlled trial of a novel intervention.

Authors:  Marya Gwadz; Charles M Cleland; Elizabeth Applegate; Mindy Belkin; Monica Gandhi; Nadim Salomon; Angela Banfield; Noelle Leonard; Marion Riedel; Hannah Wolfe; Isaiah Pickens; Kelly Bolger; DeShannon Bowens; David Perlman; Donna Mildvan
Journal:  AIDS Behav       Date:  2015-10

2.  HIV prevention, treatment, and care for people who inject drugs.

Authors:  Sarah Larney; Nickolas D Zaller; Josiah D Rich
Journal:  J Infect Dis       Date:  2013-04-16       Impact factor: 5.226

3.  Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings.

Authors:  Sarah Larney; Madeline K Mahowald; Nicholas Scharff; Timothy P Flanigan; Curt G Beckwith; Nickolas D Zaller
Journal:  Am J Public Health       Date:  2014-04-17       Impact factor: 9.308

4.  Importance of Public-Private Partnerships: Strengthening Laboratory Medicine Systems and Clinical Practice in Africa.

Authors:  Ritu Shrivastava; Renuka Gadde; John N Nkengasong
Journal:  J Infect Dis       Date:  2016-04-15       Impact factor: 5.226

5.  Alcohol and drug use outcomes among vulnerable women living with HIV: results from the Western Cape Women's Health CoOp.

Authors:  William Zule; Bronwyn Myers; Tara Carney; Scott P Novak; Kaitlin McCormick; Wendee M Wechsberg
Journal:  AIDS Care       Date:  2014-07-21

6.  Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.

Authors:  Lincoln Pac; Mara Murray Horwitz; Anne Marion Namutebi; Brandon J Auerbach; Aggrey Semeere; Teddy Namulema; Miriam Schwarz; Robert Bbosa; Allan Muruta; David B Meya; Yukari C Manabe
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

7.  Post-2015 tuberculosis strategies in a pre-2015 world.

Authors:  David W Dowdy; Richard E Chaisson
Journal:  Int J Tuberc Lung Dis       Date:  2013-02       Impact factor: 2.373

Review 8.  Mucosal immunology of HIV infection.

Authors:  Huanbin Xu; Xiaolei Wang; Ronald S Veazey
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

9.  Antiretroviral therapy for the prevention of HIV transmission: what will it take?

Authors:  Margaret L McNairy; Wafaa M El-Sadr
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

10.  Future of phylogeny in HIV prevention.

Authors:  Bluma G Brenner; Mark A Wainberg
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.